EUnetHTA Joint Action 3 (2016 – 2020)

Home  /  Activities   /  EUnetHTA Joint Action 3 (2016 – 2020) (Page 4)

We are pleased to announce that, as of today, the draft methodological guideline "Practical considerations when critically assessing economic evaluations", produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 11th October, 2019.   Objective of the

The methodological guideline ''Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness” is currently under revision by IQWiG, NIPHNO and AETSA. It will be made available for public consultation as of beginning of August for

This is a friendly reminder that EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Please be advised that input submissions will be received through

We are pleased to announce that the final assessment for OTCA15 “Irreversible electroporation in liver and pancreatic cancer", together with the input from external experts and manufacturers, are now available for access. Irreversible electroporation (IRE) is a nonthermal ablative method based on

EUnetHTA recently started a new Collaborative Assessment on a Medical Device for rectum spacers for prostate cancer radiotherapy. To find out about participation, please read more here. Input submissions will be received through EOB, Friday 5th July.

EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Input submissions will be received through 13:00, July 15th.